Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the ...

Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.
24/7 Wall St.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121 ...

'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial

Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of ...

Why is Moderna stock up 87% today during premarket trade?

The late-stage melanoma trial with Merck’s Keytruda shows both lower recurrence and less spread, with no new safety ...